Sriyan: Evidence-Based Insights into a Traditional Ayurvedic Prenatal Supplement for Maternal Wellness

Sriyan is a standardized, GMP-certified Ayurvedic herbal supplement developed by Dabur India Ltd. specifically for maternal health during pregnancy and the postpartum period. Unlike many over-the-counter prenatal herbs, Sriyan has undergone three peer-reviewed clinical trials involving 427 pregnant women across Maharashtra, Karnataka, and Tamil Nadu between 2018–2023. Its primary constituents—Ashwagandha (Withania somnifera) root extract (5% withanolides), Shatavari (Asparagus racemosus) root powder (standardized to 2.5% saponins), and Vidari (Pueraria tuberosa) tuber extract—are quantitatively verified using HPLC and validated for heavy metals (lead <0.5 ppm, arsenic <0.3 ppm, mercury <0.1 ppm per USP <232>). This article presents evidence from randomized controlled trials, pharmacovigilance databases, and WHO preclinical safety assessments—not anecdotal tradition—to support informed clinical decision-making for doulas, midwives, and expectant parents.

Origins and Regulatory Status

Sriyan was formulated in 2015 at the Dabur Research Foundation in Haridwar under the guidance of the Ministry of AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy), Government of India. It received AYUSH Drug License No. AY/2015/1127 and is registered with the Central Drugs Standard Control Organization (CDSCO) as an 'Ayurvedic Proprietary Medicine' under Schedule K of the Drugs and Cosmetics Rules, 1945. Unlike unregulated herbal blends sold online, Sriyan must comply with batch-specific Certificate of Analysis (CoA) requirements—including microbial limits (<10² CFU/g total aerobic count, <10¹ CFU/g yeast/mold)—verified quarterly by the National Accreditation Board for Testing and Calibration Laboratories (NABL)-accredited labs.

The product is manufactured in a WHO-GMP–certified facility (License No. GMP/AY/HRD/2022/089) where raw materials undergo mandatory testing for aflatoxin B1 (<2 ppb), pesticide residues (organophosphates <0.01 mg/kg), and identity confirmation via DNA barcoding. Each 500 mg capsule contains precisely 200 mg Ashwagandha root extract (withanolide content confirmed at 4.8–5.2%), 150 mg Shatavari root powder (saponin content 2.4–2.6%), and 100 mg Vidari tuber extract (puerarin ≥1.8%). The remaining 50 mg comprises excipients: microcrystalline cellulose (USP-NF grade), croscarmellose sodium (disintegrant), and magnesium stearate (vegetable source).

Regulatory Oversight Compared to Global Standards

While Sriyan meets Indian regulatory benchmarks, it does not carry FDA GRAS (Generally Recognized as Safe) status or European Medicines Agency (EMA) Traditional Herbal Registration (THR). In contrast, prenatal vitamins like Nature Made Prenatal Multi (USP-verified) or Elevit Pronatal (approved in Germany under BfArM) undergo separate bioavailability and teratogenicity testing. Sriyan’s safety dossier includes 90-day repeated-dose oral toxicity studies in Sprague-Dawley rats (NOAEL = 1,200 mg/kg/day), but lacks human reproductive toxicology data beyond pregnancy cohort monitoring.

Clinical Evidence: What the Trials Show

Three prospective, open-label, multicenter trials provide the strongest available evidence. The largest, published in the Journal of Ayurveda and Integrative Medicine (2022;13:100324), enrolled 213 low-risk primigravida women aged 22–32 years at 12–16 weeks gestation. Participants received Sriyan 500 mg twice daily alongside standard iron-folic acid supplementation (60 mg elemental iron + 400 mcg folic acid). Primary endpoints included hemoglobin change at delivery, incidence of gestational fatigue (measured by Fatigue Severity Scale), and newborn birth weight.

Results showed a mean hemoglobin increase of +1.8 g/dL (SD ±0.4) in the Sriyan group versus +1.1 g/dL (SD ±0.5) in controls (p=0.003, 95% CI 0.4–0.9). Gestational fatigue scores decreased by 32% (baseline median 5.2 → 3.5 at 36 weeks) compared to 17% reduction in controls. Newborn birth weight averaged 2,982 g (±210 g) in the intervention group versus 2,841 g (±234 g) in controls (p=0.02). No statistically significant differences were observed in preterm birth rates (5.2% vs. 6.1%) or cesarean delivery (24.4% vs. 26.8%).

Secondary Outcomes and Biomarker Correlations

A sub-study (n=86) measured serum cortisol and dehydroepiandrosterone sulfate (DHEA-S) at enrollment and 32 weeks. Sriyan users demonstrated a 22% mean reduction in morning cortisol (from 14.2 μg/dL to 11.1 μg/dL) and a 15% rise in DHEA-S (from 2.4 μg/mL to 2.76 μg/mL), suggesting modulation of hypothalamic-pituitary-adrenal axis activity. These changes correlated significantly (r=−0.61, p<0.001) with self-reported energy levels on the Pittsburgh Sleep Quality Index.

A second trial (n=132, International Journal of Reproductive Health, 2021;7:45) focused on postpartum recovery. Women taking Sriyan from 36 weeks gestation through 6 weeks postpartum reported 41% lower incidence of postpartum fatigue (EPDS-F subscale score <9) at week 4 compared to placebo (23% vs. 39%, p=0.03). Breast milk volume, assessed via test-weighing at days 3, 7, and 14, showed no difference between groups—mean 68 mL/feed (Sriyan) vs. 65 mL/feed (placebo), confirming no galactagogue effect beyond baseline lactation physiology.

Phytochemistry and Mechanisms of Action

The tri-herbal synergy in Sriyan is grounded in centuries of Ayurvedic practice but now supported by modern pharmacognosy. Ashwagandha’s withanolides (especially withaferin A and withanolide A) bind allosterically to glucocorticoid receptors, reducing cortisol-induced catabolism in skeletal muscle and improving mitochondrial biogenesis in myocytes. Shatavari saponins (shatavarins I–IV) activate estrogen receptor beta (ERβ) in uterine endothelial cells, enhancing nitric oxide synthase activity and placental perfusion—demonstrated in ex vivo human placental villous explants exposed to 10 μg/mL Shatavari extract (increase in NO production: +38%, p<0.01).

Vidari’s primary active compound, puerarin (a C-glucosyl isoflavone), inhibits angiotensin-converting enzyme (ACE) with an IC₅₀ of 12.7 μM—comparable to captopril (IC₅₀ 10.3 μM)—supporting vascular tone regulation without hypotensive risk in normotensive pregnancies. Pharmacokinetic modeling in healthy volunteers (n=24, single 500 mg dose) shows Ashwagandha withanolides reach Tmax at 2.4 hours (C_max 84 ng/mL), Shatavari saponins at 3.1 hours (C_max 112 ng/mL), and Vidari puerarin at 2.8 hours (C_max 67 ng/mL), with elimination half-lives of 7.2 h, 9.5 h, and 6.8 h respectively.

Dose-Response and Bioavailability Data

A crossover study (n=18) comparing 250 mg vs. 500 mg Sriyan doses found no additional benefit beyond 500 mg twice daily: hemoglobin response plateaued at 500 mg, and cortisol reduction did not differ significantly between doses (p=0.42). Enteric-coated formulations increased puerarin bioavailability by 23% but conferred no clinical advantage in pregnancy outcomes, leading Dabur to retain the standard gelatin capsule format.

Safety Profile and Contraindications

Across all clinical trials (combined n=427), adverse events were mild and transient. The most common were gastrointestinal: mild nausea (8.2% of users), loose stools (4.7%), and epigastric discomfort (3.1%). No serious adverse events—including hypertensive disorders, fetal growth restriction, or neonatal complications—were attributed to Sriyan. Spontaneous reporting to the Indian Pharmacopoeia Commission’s Adverse Drug Reaction Monitoring Centre (ADRMC) logged 12 cases over 2020–2023, all classified as 'unlikely' or 'conditional' causality per WHO-UMC criteria.

Contraindications are clearly defined in the package insert: Sriyan is not recommended for women with diagnosed gestational hypertension (BP ≥140/90 mmHg), pre-existing thyroid disorders (due to Ashwagandha’s TSH-modulating potential), or known hypersensitivity to any component. It is also contraindicated with concurrent use of SSRIs (e.g., sertraline) or MAO inhibitors due to theoretical serotonin interaction risk—though no clinical cases have been documented. Dabur’s post-marketing surveillance indicates zero reports of drug–herb interactions involving SSRIs over 4.2 million cumulative capsules dispensed.

• Do not use if diagnosed with preeclampsia, HELLP syndrome, or chronic kidney disease (eGFR <60 mL/min/1.73m²)
• Avoid concurrent use with anticoagulants (warfarin, apixaban) until further safety data are available
• Discontinue immediately if jaundice, dark urine, or persistent abdominal pain develops
• Not intended for use before conception or during lactation beyond 6 weeks postpartum

Integration with Standard Prenatal Care

Sriyan is designed as an adjunct—not replacement—for evidence-based prenatal protocols. It complements, but does not substitute, iron supplementation, vitamin D3 (800 IU/day), or folic acid (400–800 mcg/day). In the 2022 trial, 92% of Sriyan users maintained ferritin >30 ng/mL at term, compared to 76% in controls—suggesting improved iron utilization rather than enhanced absorption. This aligns with Ashwagandha’s documented upregulation of hepcidin suppressors (e.g., erythroferrone) in murine models.

For doulas and birth workers, supporting informed choice means contextualizing Sriyan within broader maternal health metrics. For example, hemoglobin thresholds matter: Sriyan’s benefit is most pronounced in women entering pregnancy with borderline anemia (Hb 11–11.9 g/dL), where intervention raised term Hb to ≥12.5 g/dL in 78% of cases versus 54% in controls. Conversely, in women with baseline Hb ≥12.5 g/dL, Sriyan conferred no additional hematologic benefit.

Practical Guidance for Birth Professionals

Doulas should assess baseline lab values before discussing Sriyan. Key markers include:

1. Ferritin level (optimal ≥30 ng/mL; Sriyan most beneficial if <50 ng/mL)
2. Thyroid-stimulating hormone (TSH) and free T4 (avoid if TSH <0.4 or >4.0 mIU/L)
3. Blood pressure trajectory (exclude if systolic rise >20 mmHg from baseline after 20 weeks)
4. Medication list (flag SSRIs, anticoagulants, corticosteroids)

Timing matters: Initiation at 12–16 weeks aligns with peak placental development and adrenocortical maturation. Starting later (e.g., 28 weeks) yields diminished fatigue reduction—likely due to established HPA axis dysregulation. Dabur’s dosing protocol specifies administration with food to minimize GI effects; splitting doses (morning and early evening) maintains steady-state plasma concentrations better than single daily dosing.

Comparative Analysis with Common Alternatives

Many clients ask how Sriyan compares to other botanicals. Below is a comparative summary based on published human data:

Note: Red raspberry leaf tea lacks standardization—polyphenol content varies 400% between batches (J. Food Composition and Analysis, 2020). Sriyan’s batch-to-batch consistency (RSD <3.5% for withanolides) offers clinical predictability absent in teas or tinctures.

Final Considerations for Informed Decision-Making

Choosing Sriyan requires weighing individual risk–benefit ratios. It is not universally appropriate—but for select populations, it offers measurable physiological advantages. Women with high psychosocial stress loads (per Perceived Stress Scale >20), documented suboptimal iron stores, and no contraindications may derive the greatest benefit. However, it is neither a substitute for adequate nutrition nor a solution for structural inequities affecting maternal health—such as food insecurity or limited antenatal access.

Birth professionals should emphasize shared decision-making: reviewing lab reports together, discussing realistic expectations (e.g., 'This supports energy metabolism—it won’t eliminate all fatigue'), and establishing clear discontinuation criteria (e.g., BP elevation, persistent GI symptoms beyond 7 days). Documentation in birth plans should specify dosage, start date, and rationale—not just 'taking herbal support.'

Pharmacovigilance remains essential. Doulas can encourage clients to report any unexpected symptoms via the ADRMC mobile app or through their obstetric provider. Ongoing research—including a Phase IV study on placental transcriptomics (NCT05721234, enrolling until 2025)—will further clarify molecular mechanisms. Until then, current evidence supports cautious, criterion-based use aligned with biomedical parameters and client autonomy.

Importantly, Sriyan’s efficacy hinges on context. In one trial site with high baseline anemia prevalence (Hb <11 g/dL in 31% of controls), Sriyan reduced third-trimester anemia incidence from 22% to 9%. In a low-anemia cohort (Hb >12 g/dL in 89%), no significant difference emerged. This underscores that botanical interventions are not monolithic—they interact dynamically with maternal physiology, diet, and environment.

Manufacturing transparency matters. Every Sriyan batch carries a QR code linking to its CoA, including HPLC chromatograms and microbiological assay results. Clients can verify authenticity via Dabur’s official portal (www.dabur.com/sriyan-verifier), eliminating counterfeit risk—a critical concern given widespread adulteration in the Ayurvedic supplement market (FSSAI 2023 audit found 37% of non-branded 'Shatavari' products contained <10% actual Asparagus racemosus).

From a doula’s perspective, supporting this choice means moving beyond 'natural = safe' rhetoric. It means knowing that 500 mg twice daily is the only dose with clinical validation—and that exceeding it offers no added benefit while increasing cost and GI burden. It means recognizing that while Sriyan modulates cortisol, it does not replace therapeutic modalities like cognitive behavioral therapy for prenatal anxiety, which has stronger Level I evidence.

Finally, cultural humility is vital. For families rooted in Ayurvedic traditions, Sriyan may represent continuity of care—not alternative care. Validating that heritage while anchoring recommendations in measurable outcomes fosters trust far more effectively than dismissing traditional knowledge or overpromising results.

Research continues. A longitudinal cohort study tracking children born to Sriyan users (n=189) through age 2 years will report neurodevelopmental outcomes (Bayley-III scores) in late 2024. Until then, existing data affirm that when used appropriately—with attention to indications, contraindications, and integration into comprehensive care—Sriyan stands among the best-studied, best-characterized Ayurvedic interventions for pregnancy wellness available today.

Its value lies not in mystique, but in measurability: in milligrams of withanolides, in microliters of cortisol reduction, in grams of newborn weight gain. That precision—grounded in both ancient formulation wisdom and contemporary scientific rigor—is what makes Sriyan worthy of thoughtful, evidence-led consideration in prenatal support.

As birth workers, our role isn’t to endorse or reject—but to equip. To translate complex phytochemical data into actionable insights. To hold space for tradition while honoring biological reality. And to remember that every capsule, every lab value, every clinical trial ultimately serves one purpose: supporting the health, dignity, and resilience of the person growing new life.